Bibliography

Cognate may provide to you on its web site and through other sites or in other media or through additional means, certain sources of information, anecdotal and published reports. Cognate makes no representation and disclaims all liability for the content, accuracy or efficacy of any such reports or information. You should not rely on any such information without further inquiry and any published or reported claims or results cannot be generalized to your personal circumstances, medical condition or state of facts.

COGNATE DOES NOT MAKE ANY CLAIMS REGARDING THE DIAGNOSIS, PREVENTION, TREATMENT OR CURE OF ANY DISEASE AND NONE OF ITS STATEMENTS HAVE BEEN REVIEWED, EVALUATED OR ENDORSED BY THE FDA.

All articles are organized alphabetically by category as follows:

  1. Alzheimer's Disease
  2. Dementia
  3. Diabetes
  4. Glucose
  5. Insulin Resistance
  6. Ketogenesis
  7. Parkinson's Disease
  8. Research of Additional Interest
Back to Top
Alzheimer's Disease
  • S. Cunnane et al. / Nutrition xxx (2010) 1-18, Brain fuel metabolism, aging, and Alzheimer's disease, Nutrition (2010), doi:10.1016/j.nut.2010.07.021
  • Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
  • Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
  • Sims NR, Bowen DM, Neary D, Davison AN. Metabolic processes in Alzheimer's disease: adenine nucleotide content and production of 14CO2 from [U-14C]glucose in vitro in human neocortex. J Neurochem 1983;41:1329-34.
  • Hoyer S, Oesterreich K, Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 1988;235:143-8. [4] Hoyer S, Oesterreich K, Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol
  • Blass JP. A new approach to treating Alzheimer's disease. Ann NY Acad Sci 2008;1147:122-8.
  • Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 2006;100:328-35.
  • Li Y, Rinne JO, Mosconi L, Pirraglia e, Rusinek H, DeSanti S, et al. Regional analysis of FDG and PIB-PeT images in normal aging, mild cognitive impairment, and Alzheimer's disease. eur J Nucl Med Molec Imag
  • Querfurth HW, LaFerla FM. Alzheimer's disease. N engl J Med 2010;362:329-44.
  • Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala eL, Hartikainen P, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein e polymorphism. Neurology 1996;46:413-9.
  • erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF, et al. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354-60.
  • Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65.
  • Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PeT in Alzheimer disease. Nat Rev Neurol 2010;6:78-87.
  • Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia e, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 2007;104:19067-72.
  • Rasgon NL, et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 2009 (Dec 21) [epub ahead of print]
  • Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004;101:3100-5.[46] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6: 734-46.
  • Mosconi L, Sorbi S, Nacmias B, De Cristofaro MT, Fayyaz M, Cellini e, et al. Brain metabolic differences between sporadic and familial Alzheimer's disease. Neurology 2003;61:1138-40.
  • Ibanez V, Pietrini P, Alexander Ge, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585-93.
  • Meltzer CC, Zubieta JK, Brandt J, Tune Le, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47:454-61.
  • Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PeT image analysis. Neurology 2005;64:1860-7.
  • Crawford JG. Alzheimer's disease risk factors as related to cerebral blood flow. Med Hypotheses 1996;46:367-77.
  • Hock C, Villringer K, Muller-Spahn F, Wenzel R, Heekeren H, Schuh- Hofer S, et al. Decrease in parietal cerebral hemoglobin oxygenation during performance of a verbal fluency task in patients with Alzheimer's disease monitored by means of near-infrared spectroscopy (NIRS)- correlation with simultaneous rCBF-PeT measurements. Brain Res 1997;755:293-303.
  • Kalaria RN, Harik SI. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 1989;53:1083-8.
  • Marcus DL, de Leon MJ, Goldman J, Logan J, Christman DR, Wolf AP, et al. Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol 1989;26:91-4.
  • Petersen RC. Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment. J Nutr Health Aging 2010;14:304-5.
  • Del Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Maggiore L, et al. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PeT study. eur J Nucl Med Molec Imag 2008;35:1357-66.
  • Dubois B, Picard G, Sarazin M. early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci 2009;11:135-9.
  • Reiman eM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloidbeta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:6820-5.
  • Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PeT changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. eur J Nucl Med Molec Imag 2009;36:811-22.
  • Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PeT follow-up study. eur J Nucl Med Molec Imag 2003;30:1104-13.
  • Ishii H, Ishikawa H, Meguro K, Tashiro M, Yamaguchi S. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project. Int Psychogeriatr 2009;21:148-56.
  • Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009;72:513-20.
  • Schlageter NL, Carson ReRapoport SI. examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]eDTA and positron emission tomography. J Cereb Blood Flow Metab 1987;7:1-8.
  • Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 2009;48:239-56.
  • Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. eur J Pharmacol 2004;490:97-113.
  • Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease
  • Steen e, Terry BM, Rivera eJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80.
  • Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. exp Gerontol 2007;42:10-21.
  • Raffaitin C, Gin H, empana JP, Helmer C, Berr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009;32:169-74.
  • Coon KD, Valla J, Szelinger S, Schneider Le, Niedzielko TL, Brown KM, et al. Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing. Mitochondrion 2006;6:194-210.
  • Hatanpaa K, Isaacs KR, Shirao T, Brady DR, Rapoport SI. Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J Neuropathol exp Neurol 1999;58:637-43.
  • Sumpter PQ, Mann DM, Davies CA, Yates PO, Snowden JS, Neary D. A ultrastructural analysis of the effects of accumulation of neurofibrillary tangle in pyramidal neurons of the cerebral cortex in Alzheimer's disease. Neuropathol Appl Neurobiol 1986;12:305-19.
  • Sorbi S, Bird eD, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 1983;13:72-8. [110] de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009;42:475-81.
  • Terry RD, Masliah e, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.
  • Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann NY Acad Sci 2008;1147:180-95.
  • Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:10804-9.
  • Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FeBS Lett 2008;582:359-64.
  • Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS, et al. Oxidative insults are associated with apolipoprotein e genotype in Alzheimer's disease brain. Neurobiol Dis 2000;7:23-37.
  • Aliev G, Palacios HH, Walrafen B, Lipsitt Ae, Obrenovich Me, Morales L. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int J Biochem Cell Biol 2009;41:1989- 2004.
  • Bailey TL, Rivara CB, Rocher AB, Hof PR. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 2004;26:573-8.
  • de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann NY Acad Sci 2002;977:196-215.
  • Pluta R. Is the ischemic blood-brain barrier insufficiency responsible for full-blown Alzheimer's disease? Neurol Res 2006;28:665-71.
  • Harik SI, LaManna JC. Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol 1991;29:573.
  • Reiman eM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein e. N engl J Med 1996;334:752-8.
  • Reiman eM, Chen K, Alexander Ge, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004;101: 284-9.
  • Reiman eM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 1998;44:288-91.
  • Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab (Lond) 2005;2:28.
  • Duara R, Barker WW, Chang J, Yoshii F, Loewenstein DA, Pascal S. Viability of neocortical function shown in behavioral activation state PeT studies in Alzheimer disease. J Cereb Blood Flow Metab 1992;12:927-34.
  • Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31.
  • Risner Me, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer's disease. Pharmacogenomics J 2006;6:246-54.
  • Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenom J 2007;7:10-28.
  • Sims NR, Bowen DM, Smith CC, Flack RH, Davison AN, Snowden JS, et al. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1980;1:333-6.
  • Kalpouzos G, eustache F, Desgranges B. [Cognitive reserve and neural networks in normal aging and Alzheimer's disease]. Psychol Neuropsychiatr Vieil 2008;6:97-105.
  • engler H, Forsberg A, Almkvist O, Blomquist G, Larsson e, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-66.
  • Patterson C, Feightner J, Garcia A, MacKnight C. General risk factors for dementia: a systematic evidence review. Alzheimers Dement 2007;3:341-7.
  • Pike Ke, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Betaamyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-44.
  • Petersen RC. early diagnosis of Alzheimer's disease: is MCI too late? Curr Alzheimer Res 2009;6:324-30.
  • Benson DF, Kuhl De, Hawkins RA, Phelps Me, Cummings JL, Tsai SY. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 1983;40:711-4.
  • Cutler NR, Haxby JV, Duara R, Grady CL, Kay AD, Kessler RM, et al. Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease. Ann Neurol 1985;18:298-309.
  • Rapoport SI. Positron emission tomography in normal aging and Alzheimer's disease. Gerontology 1986;32:6-13.
  • Alavi A, Newberg AB, Souder e, Berlin JA. Quantitative analysis of PeT and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 1993;34:1681-7.
  • Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPeT and FDG PeT in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. eur J Nucl Med 1994;21:1052-60.
  • Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl De. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94. S. Cunnane et al. / Nutrition xxx (2010) 1-18 17
  • Rimajova M, Lenzo NP, Wu JS, Bates KA, Campbell A, Dhaliwal SS, et al. Fluoro-2-deoxy-D-glucose (FDG)-PeT in APOeepsilon4 carriers in the Australian population. J Alzheimers Dis 2008;13:137-46.
  • Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). NeuroImage 2009;45:1107-16.
  • Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward J, Roques P, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995;186:17-20.
  • Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006;47:1778-86.
  • Costantini LC, et al. Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008;9(Suppl 2):516.
  • Freund-Levi Y, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63:1402-8.
  • Henderson ST. Study of the ketogenic agent AC-1202 [MCT] in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31. http://www.nutritionandmetabolism.com/content/6/1/31
  • Jicha GA, Markesbery WR. Omega-3 fatty acids: potential role in the management in early Alzheimer's disease. Clinical Interventions in Aging 2010;5:45-61.
  • Kashiwaya Y, Clarke K, Veech RL. 2000. D-ß-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc National Acad Sci USA 2000; 97:5440-4. Available at http://dx.doi.org/10.1073/pnas.97.10.5440.
  • Plastino M, et al. effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010:288:112-6.
  • Rasgon NL, et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 2009 (Dec 21) [epub ahead of print]
  • Reger MA, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440-8.
  • Schaefer eJ, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease. The Framingham Heart Study. Arch Neurol 2006;63:1545-50.
  • Fang Cheng, et al. Treatment with vitamin C dissolves toxic protein aggregates in Alzheimer's disease. Journal of Biological Chemistry, 286, 27559-27572, 2011.
Back to Top
Dementia
  • Canadian Study of Health, and Aging Working Group. Canadian Study of Health and Aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.
  • Brayne C, Gao L, Dewey M, Matthews Fe. Dementia before death in ageing societies-the promise of prevention and the reality. PLoS Med 2006;3:e397.
  • erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF, et al. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354-60.
  • Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80:S160-7.
  • Petersen RC. Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment. J Nutr Health Aging 2010;14:304-5.
  • Chertkow H, Massoud F, Nasreddine Z, Belleville S, Joanette Y, Bocti C, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 2008;178:1273-85.
  • Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 1992;40:1129-34.
  • Schlageter NL, Carson ReRapoport SI. examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]eDTA and positron emission tomography. J Cereb Blood Flow Metab 1987;7:1-8.
  • Raffaitin C, Gin H, empana JP, Helmer C, Berr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009;32:169-74.
  • Deschamps V, Barberger-Gateau P, Peuchant e, Orgogozo JM. Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxidative stress. Neuroepidemiology 2001;20:7-15.
  • Lassen NA, Munck O, Tottey eR. Mental function and cerebral oxygen consumption in organic dementia. AMA Arch Neurol Psychiatry 1957;77:126-33.
  • Bowen DM,White P, Spillane JA, Goodhardt MJ, Curzon G, Iwangoff P, et al. Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet 1979;1:11-4.
  • Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab 2006;32:403-14.
  • Reiman eM, Chen K, Alexander Ge, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004;101: 284-9.
  • Patterson C, Feightner J, Garcia A, MacKnight C. General risk factors for dementia: a systematic evidence review. Alzheimers Dement 2007;3:341-7.
  • Pike Ke, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Betaamyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-44.
  • Sliwinski MJ, Hofer SM, Hall C, Buschke H, Lipton RB. Modeling memory decline in older adults: the importance of preclinical dementia, attrition, and chronological age. Psychol Aging 2003;18:658-71.
  • Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981;104:753-78.
  • Benson DF, Kuhl De, Hawkins RA, Phelps Me, Cummings JL, Tsai SY. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 1983;40:711-4.
  • Chawluk JB, Alavi A, Dann R, Hurtig HI, Bais S, Kushner MJ, et al. Positron emission tomography in aging and dementia: effect of cerebral atrophy. J Nucl Med 1987;28:431-7.
  • Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPeT and FDG PeT in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. eur J Nucl Med 1994;21:1052-60.
Back to Top
Diabetes
  • Oz G, Kumar A, Rao JP, Kodl CT, Chow L, eberly Le, et al. Human brain glycogen metabolism during and after hypoglycemia. Diabetes 2009;58:1978-85.
  • Balasse eO, Fery F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev 1989;5:247-70.
  • Steen e, Terry BM, Rivera eJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80.
  • Raffaitin C, Gin H, empana JP, Helmer C, Berr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009;32:169-74.
  • Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. endocr Rev 2002;23:201-29.
  • Wolfrum C, Asilmaz e, Luca e, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004;432:1027-32.
  • Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 2000;49:399-408.
  • Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab 2006;32:403-14.
  • Hawkins RA, Mans AM, Davis DW. Regional ketone body utilization by rat brain in starvation and diabetes. Am J Physiol 1986;250:e169-78.
  • Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes 1994;43:1311-7.
  • Page KA, Williamson A, Yu N, McNay eC, Dzuira J, McCrimmon RJ, et al. Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes 2009;58:1237-44.
  • Plastino M, et al. effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010:288:112-6.
Back to Top
Glucose
  • Heininger K. The cerebral glucose-fatty acid cycle: evolutionary roots, regulation, and (patho)physiological importance. Int Rev Neurobiol 2002;51:103-58.
  • Duelli R, Kuschinsky W. Brain glucose transporters: relationship to local energy demand. News Physiol Sci 2001;16:71-6.
  • Leybaert L, De Bock M, Van Moorhem M, Decrock e, De Vuyst e. Neurobarrier coupling in the brain: adjusting glucose entry with demand. J Neurosci Res 2007; 85:3213-20.
  • Barros LF, Porras OH, Bittner CX. Why glucose transport in the brain matters for PeT. Trends Neurosci 2005;28:117-9.
  • Phelps Me, Huang SC, Hoffman eJ, Selin C, Sokoloff L, Kuhl De. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-88.
  • Sokoloff L. Measurement of local cerebral glucose utilization and its relation to local functional activity in the brain. Adv exp Med Biol 1991;291:21-42.
  • Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
  • Lear JL, Ackerman RF. Comparison of regional blood-brain transport kinetics between glucose and fluorodeoxyglucose. J Nucl Med 1992;33:1819-24.
  • Ibanez V, Pietrini P, Furey ML, Alexander Ge, Millet P, Bokde AL, et al. Resting state brain glucose metabolism is not reduced in normotensive healthy men during aging, after correction for brain atrophy. Brain Res Bull 2004;63:147-54.
  • Pifferi F, Roux F, Langelier B, Alessandri JM, Vancassel S, Jouin M, et al. (n-3) polyunsaturated fatty acid deficiency reduces the expression of both isoforms of the brain glucose transporter GLUT1 in rats. J Nutr 2005;135:2241-6.
  • Ximenes da Silva A, Lavialle F, Gendrot G, Guesnet P, Alessandri JM, Lavialle M. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J Neurochem 2002;81:1328-37.
  • Pifferi F, Jouin M, Alessandri JM, Haedke U, Roux F, Perriere N, et al. n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. Prostaglandins Leukot essent Fatty Acids 2007;77:279-86.
  • Pifferi F, Jouin M, Alessandri JM, Roux F, Perrière N, Langelier B, et al. n-3 long-chain fatty acids and regulation of glucose transport in two models of rat brain endothelial cells. Neurochem Int 2010;56:703-10.
  • elahi D, Muller DC, egan JM, Andres R, Veldhuist J, Meneilly GS. Glucose tolerance, glucose utilization and insulin secretion in ageing. Novartis Found Symp 2002;242:222-42. discussion 242-6.
  • Floras JS, Meneilly G. Insulin-mediated blood flow and glucose uptake. Can J Cardiol 2001;17:7A-10A.
  • Sims NR, Bowen DM, Davison AN. [14C]acetylcholine synthesis and [14C] carbon dioxide production from [U-14C]glucose by tissue prisms from human neocortex. Biochem J 1981;196:867-76.
  • Borowsky IW, Collins RC. Metabolic anatomy of brain: a comparison of regional capillary density, glucose metabolism, and enzyme activities. J Comp Neurol 1989;288:401-13.
  • Pardridge WM. Blood-brain barrier transport of glucose, free fatty acids, and ketone bodies. Adv exp Med Biol 1991;291:43-53.
  • Willis MW, Ketter TA, Kimbrell TA, George MS, Herscovitch P, Danielson AL, et al. Age, sex and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Res 2002;114:23-37.
  • Croteau e, Lavallee e, Labbe SM, Hubert L, Pifferi F, Rousseau JA, et al. Image-derived input function in dynamic human PeT/CT: methodology and validation with 11Cacetate and 18F-fluorothioheptadecanoic acid in muscle and 18F-fluorodeoxyglucose in brain. eur J Nucl Med Molec Imag; 2010 (in press).
  • Kalpouzos G, Chetelat G, Baron JC, Landeau B, Mevel K, Godeau C, et al. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging 2009;30:112-24.
  • Petit-Taboue MC, Landeau B, Desson JF, Desgranges B, Baron JC. effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. NeuroImage 1998;7:176-84.
  • Horwitz B, Duara R, Rapoport SI. Age differences in intercorrelations between regional cerebral metabolic rates for glucose. Ann Neurol 1986;19:60-7.
  • Duara R, Margolin RA, Robertson-Tchabo eA, London eD, Schwartz M, Renfrew JW, et al. Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years. Brain 1983;106:761-75.
  • Duara R, Grady C, Haxby J, Ingvar D, Sokoloff L, Margolin RA, et al. Human brain glucose utilization and cognitive function in relation to ageAnn Neurol 1984;16:703-13.
  • De Santi S, de Leon MJ, Convit A, Tarshish C, Rusinek H, Tsui WH, et al. Age-related changes in brain: II. Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. Psychiatr Q 1995;66:357-70.
  • Bentourkia M, Bol A, Ivanoiu A, Labar D, Sibomana M, Coppens A, et al. Comparison of regional cerebral blood flow and glucose metabolism in the normal brain: effect of aging. J Neurolog Sci 2000;181:19-28.
  • de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F] fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PeT). Proc Natl Acad Sci USA 2001;98:10966-71.
  • Rimajova M, Lenzo NP, Wu JS, Bates KA, Campbell A, Dhaliwal SS, et al. Fluoro-2-deoxy-D-glucose (FDG)-PeT in APOeepsilon4 carriers in the Australian population. J Alzheimers Dis 2008;13:137-46.
  • LaManna JC, et al. Ketones suppress brain glucose consumption. Adv exp Med Biol 2009;645:301-6.
Back to Top
Insulin Resistance
  • Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2009;300:1140-2.
  • Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. endocr Rev 2002;23:201-29.
  • de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009;42:475-81.
  • Hallschmid M, Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders. Diabetologia 2009;52:2264-9.
Back to Top
Ketogenesis
  • VanItallie TB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005;64:728-30.
  • Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot essent Fatty Acids 2004;70:309-19.
  • Gottstein VU, Held K, Muller W, Berghoff W. Utilization of ketone bodies by the human brain. In: Meyer JS, Reivich M, Lecher H, Thomas CC, editors. Research on cerebral circulation. Thomas CC, Springfield: 5th International Salzburg Conference; 1970. p. 137-45.
  • Hasselbalch SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, et al. Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. Am J Physiol 1996;270:e746-51.
  • Bergen SS, Hashim SA, VanItallie TB. Hyperketonemia induced in man by medium chain triglyceride. Diabetes 1966;15:723-5.
  • Pi-Sunyer FX, Hashim SA, VanItallie TB. Insulin and ketone responses to ingestion of medium and long-chain triglycerides in man. Diabetes 1969;18:96-100. [21] Lying-Tunell U, Lindblad BS, Malmlund HO, Persson B. Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol Scand 1981;63:337-50.
  • Lying-Tunell U, Lindblad BS, Malmlund HO, Persson B. Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol Scand 1981;63:337-50.
  • Pan JW, Telang FW, Lee JH, de Graaf RA, Rothman DL, Stein DT, et al. Measurement of beta-hydroxybutyrate in acute hyperketonemia in human brain. J Neurochem 2001;79:539-44.
  • Balasse eO, Fery F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev 1989;5:247-70.
  • Soeters MR, Sauerwein HP, Faas L, Smeenge M, Duran M,Wanders RJ, et al. effects of insulin on ketogenesis following fasting in lean and obese men. Obesity (Silver Spring) 2009;17:1326-31.
  • Fernandez-Figares I, Shannon Ae, Wray-Cahen D, Caperna TJ. The role of insulin, glucagon, dexamethasone, and leptin in the regulation of ketogenesis and glycogen storage in primary cultures of porcine hepatocytes prepared from 60 kg pigs. Domest Anim endocrinol 2004;27: 125-40.
  • ] Hasselbalch SG, Knudsen GM, Jakobsen J, Hageman LP, Holm S, Paulson OB. Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans. Am J Physiol
  • Lying-Tunell U, Lindblad BS, Malmlund HO, Persson B. Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol Scand 1980;62:265-75.
  • ] Kuhl De, Metter eJ, Riege WH, Phelps Me. effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 1982;2:163-71.
  • Ruderman NB, Ross PS, Berger M, Goodman MN. Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J
  • Tremblay S, Ouellet R, Rodrigue S, Langlois R, Benard F, Cunnane SC. Automated synthesis of 11C-acetoacetic acid, a key alternate brain fuel to glucose. Appl Radiat Isot 2007;65:934-40.
  • Klepper J. Impaired glucose transport into the brain: the expanding spectrum of glucose transporter type 1 deficiency syndrome. Curr Opin Neurol 2004;17:193-6.
  • Amiel SA, Archibald HR, Chusney G, Williams AJ, Gale eA. Ketone infusion lowers hormonal responses to hypoglycaemia: evidence for acute cerebral utilization of a non-glucose fuel. Clin Sci (Lond) 1991;81:189-94. [97] Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot essent Fatty Acids 2004;70:243-51.
  • Wolfrum C, Asilmaz e, Luca e, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004;432:1027-32.
  • Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006;60:223-35.
  • Studzinski CM, MacKay WA, Beckett TL, Henderson ST, Murphy MP, Sullivan PG, et al. Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. Brain Res 2008;1226:209-17.
  • Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev 1980;60:143-87.
  • Guzman M, Blazquez C. Is there an astrocyte-neuron ketone body shuttle? Trends endocrinol Metab 2001;12:169-73.
  • Pardridge WM. Blood-brain barrier transport of glucose, free fatty acids, and ketone bodies. Adv exp Med Biol 1991;291:43-53.
  • Daniel PM, Love eR, Moorehouse SR, Pratt Oe, Wilson P. Factors influencing utilisation of ketone-bodies by brain in normal rats and rats with ketoacidosis. Lancet 1971;2:637-8.
  • Hawkins RA, Mans AM, Davis DW. Regional ketone body utilization by rat brain in starvation and diabetes. Am J Physiol 1986;250:e169-78.
  • Bentourkia M, Tremblay S, Pifferi F, Rousseau J, Lecomte R, Cunnane S. PeT study of 11C-acetoacetate kinetics in rat brain during dietary treatments affecting ketosis. Am J Physiol endocrinol Metab 2009;296:e796-801.
  • Hasselbalch SG, Knudsen GM, Jakobsen J, Hageman LP, Holm S, Paulson OB. Blood-brain barrier permeability of glucose and ketone bodies during short-term starvation in humans. Am J Physiol 1995;268:e1161-6.
  • Blomqvist G, Alvarsson M, Grill V, Von Heijne G, Ingvar M, Thorell JO, et al. effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients. Am J Physiol endocrinol Metab 2002;283:e20-8.
  • Morris AA. Cerebral ketone body metabolism. J Inherit Metab Dis 2005;28:109-21.
  • Musa-Veloso K, Likhodii SS, Cunnane SC. Breath acetone is a reliable indicator of ketosis in adults consuming ketogenic meals. Am J Clin Nutr 2002;76:65-70.
  • Musa-Veloso K, Likhodii SS, Rarama e, Benoit S, Liu YM, Chartrand D, et al. Breath acetone predicts plasma ketone bodies in children with epilepsy on a ketogenic diet. Nutrition 2006;22:1-8.
  • Leino RL, Gerhart DZ, Duelli R, enerson Be, Drewes LR. Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem Int 2001;38:519-27.
  • Ruderman NB, Ross PS, Berger M, Goodman MN. Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J 1974;138:1-10.
  • Wiener R, Hirsch HJ, Spitzer JJ. Cerebral extraction of ketones and their penetration into CSF in the dog. Am J Physiol 1971;220:1542-6.
  • Pifferi F, Tremblay S, Plourde M, Tremblay-Mercier J, Bentourkia M, Cunnane SC. Ketones and brain function: possible link to polyunsaturated fatty acids and availability of a new brain PeT tracer, 11C-acetoacetate. epilepsia 2008;49:76-9.
  • Falk Re, Cederbaum SD, Blass JP, Gibson Ge, Kark RA, Carrel Re. Ketonic diet in the management of pyruvate dehydrogenase deficiency. Pediatrics 1976;58:713-21.
  • Amiel SA, Archibald HR, Chusney G, Williams AJ, Gale eA. Ketone infusion lowers hormonal responses to hypoglycaemia: evidence for acute cerebral utilization of a non-glucose fuel. Clin Sci (Lond) 1991;81:189-94.
  • Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes 1994;43:1311-7.
  • Prins ML. Cerebral metabolic adaptation and ketone metabolism after brain injury. J Cereb Blood Flow Metab 2008;28:1-16.
  • Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab (Lond) 2005;2:28.
  • Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot essent Fatty Acids 2004;70:309-19.
  • Freemantle e, Vandal M, Tremblay Mercier J, Plourde M, Poirier J, Cunnane SC. Metabolic response to a ketogenic breakfast in the healthy elderly. J Nutr Health Aging 2009;13:293-8.
  • Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31.
  • Freund G, Weinsier RL. Standardized ketosis in man following medium chain triglyceride ingestion. Metabolism 1966;15:980-91.
  • Cross TA, Pahl C, Oberhansli R, Aue WP, Keller U, Seelig J. Ketogenesis in the living rat followed by 13C NMR spectroscopy. Biochemistry 1984;23:6398-402.
  • Blomqvist G, Thorell JO, Ingvar M, Grill V, Widen L, Stone-elander S. Use of R-beta-[1-11C]hydroxybutyrate in PeT studies of regional cerebral uptake of ketone bodies in humans. Am J Physiol 1995;269:e948-59.
  • Balietti M, et al. A ketogenic diet increases succinic dehydroganase (SDH) activity and recovers age-related decrease in numeric density of SDH-positive mitochondria in cerebellar Purkinje cells of late-adult rats. Micron 2010;41:143-8.
  • Bergen SS, Hashim SA, VanItallie TB. Hyperketonemia induced in man by medium chain triglyceride. Diabetes 1966;15:723-5.
  • Cornille e, et al. enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury. BMC Neuroscience 2010;11:51.
  • Gandey A. Ketogenic diet gaining popularity in epilepsy. 2009. http://www.medscape.com/viewarticle/714005_print
  • Henderson ST. Study of the ketogenic agent AC-1202 [MCT] in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31. http://www.nutritionandmetabolism.com/content/6/1/31
  • Kwiterovich, P.O., e.P.G. Vining, et al. 2003. effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 2003;290:912-20. Abstract available at http://dx.doi.org/10.1001/jama.290.7.912.
  • LaManna JC, et al. Ketones suppress brain glucose consumption. Adv exp Med Biol 2009;645:301-6.
  • Pan JW, et al. Human brain beta-hydroxybutyrate and lactate increase in fasting-induced ketosis. J Cereb Blood Flow Metab 2000.
  • Pi-Sunyer FX, Hashim SA, VanItallie TB. Insulin and ketone responses to ingestion of medium and long-chain triglycerides in man. Diabetes 1969;18:96-100.
  • Taha AY, et al. Despite transient ketosis, the classic high-fat ketogenic diet induces marked changes in fatty acid metabolism in rats. Metab Clin exp 2005;54:1127-1132)
  • VanItallie TB, Nufert TH. Ketones: metabolism's ugly duckling. Nutr Rev 2003; 61:327-41.
  • Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. IUBMB Life 2001;51:241-7. Abstract available at http://dx.doi.org/10.1080/152165401753311780
Back to Top
Parkinson's Disease
  • VanItallie TB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005;64:728-30.
  • VanItallie TB. Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction. Metabolism 2008;57:S50-5
  • Kashiwaya Y, Clarke K, Veech RL. 2000. D-ß-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc National Acad Sci USA 2000; 97:5440-4. Available at http://dx.doi.org/10.1073/pnas.97.10.5440.
  • Tieu K, Przedborski S. D-ß-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 2003:112:892-901. Available at http://dx.doi.org/10.1172/JCI200318797
Back to Top
Research of Additional Interest
  • Holliday MA. Metabolic rate and organ size during growth from infancy to maturity and during late gestation and early infancy. Pediatrics 1971;47 (suppl 2):169+.
  • Sokoloff L. energetics of functional activation in neural tissues. Neurochem Res 1999;24:321-9.
  • Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci 2002;25:621-5.
  • Shulman RG, Rothman DL, Behar KL, Hyder F. energetic basis of brain activity: implications for neuroimaging. Trends Neurosci 2004;27:489-95.
  • Purdon AD, Rapoport SI. energy consumption by phospholipid metabolism in mammalian brain. New York: Springer; 2007.
  • Magistretti PJ. Brain energy metabolism. In: Bryrne JH, Roberts JL, editors. An introducation to cellular and molecular neuroscience. Hong Kong: Academic Press; 2004. p. 67-90.
  • Pellerin L, Bouzier-Sore AK, Aubert A, Serres S, Merle M, Costalat R, et al. Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 2007;55:1251-62.
  • Owen Oe, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr. Brain metabolism during fasting. J Clin Invest 1967;46:1589-95.
  • O'Sullivan F, Muzi M, Spence AM, Mankoff DM, O'Sullivan JN, Fitzgerald N, et al. Nonparametric residue analysis of dynamic PeT data with application to cerebral fdg studies in normals. J Am Stat Assoc 2009;104:556-71.
  • Kimura N, Yamamoto Y, Kameyama R, Hatakeyama T, Kawai N, Nishiyama Y. Diagnostic value of kinetic analysis using dynamic 18F-FDGPeT in patients with malignant primary brain tumor. Nucl Med Commun 2009;30:602-9.
  • Gunn RN, Gunn SR, Turkheimer Fe, Aston JA, Cunningham VJ. Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 2002;22:1425-39.
  • Graham MM, Muzi M, Spence AM, O'Sullivan F, Lewellen TK, Link JM, et al. The FDG lumped constant in normal human brain. J Nucl Med 2002;43:1157-66.
  • Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000;27:643-6.
  • Krohn KA, Muzi M, Spence AM. What is in a number? The FDG lumped constant in the rat brain. J Nucl Med 2007;48:5-7.
  • Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004;45:1431-4.
  • Silverman DH, Mosconi L, ercoli L, Chen W, Small GW. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Sem Nucl Med 2008;38:251-61.
  • Petersen RC, Smith Ge, Waring SC, Ivnik RJ, Tangalos eG, Kokmen e. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
  • Reiman eM, Chen K, Alexander Ge, Caselli RJ, Bandy D, Osborne D, et al. Correlations between apolipoprotein e epsilon4 gene dose and brainimaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 2005;102:8299-302.
  • Bourre JM, Francois M, Youyou A, Dumont O, Piciotti M, Pascal G, et al. The effects of dietary alpha-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. J Nutr 1989;119:1880-92.
  • Kitajka K, Sinclair AJ, Weisinger RS, Weisinger HS, Mathai M, Jayasooriya AP, et al. effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci USA 2004;101: 10931-6.
  • Brenna JT, Diau GY. The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot essent Fatty Acids 2007;77: 247-50.
  • Plourde M, Vohl MC, Vandal M, Couture P, Lemieux S, Cunnane SC. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoe epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. Br J Nutr 2009;102:1121-4.
  • Fortier M, Tremblay-Mercier J, Plourde M, Chouinard-Watkins R, Vandal M, Pifferi F, et al. Higher plasma n-3 fatty acid status in the moderately healthy elderly in southern Quebec: higher fish intake or aging-related change in n-3 fatty acid metabolism? Prostaglandins Leukot essent Fatty Acids 2010;82:277-80.
  • de Groot RH, van Boxtel MP, Schiepers OJ, Hornstra G, Jolles J. Age dependence of plasma phospholipid fatty acid levels: potential role of linoleic acid in the age-associated increase in docosahexaenoic acid and eicosapentaenoic acid concentrations. Br J Nutr 2009;102:1058-64.
  • Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005;64:1348-53.
  • Bortz WM 2nd. A conceptual framework of frailty: a review. J Gerontol A Biol Sci Med Sci 2002;57:M283-8.
  • Bruce-Keller AJ, Keller JN, Morrison CD. Obesity and vulnerability of the CNS. Biochim Biophys Acta 2009;1792:395-400.
  • Carpentier AC, Frisch F, Cyr D, Genereux P, Patterson BW, Giguere R, et al. On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans. Am J Physiol endocrinol Metab 2005;289:e849-56.
  • Schapira AH. Mitochondrial disease. Lancet 2006;368:70-82.
  • Gibson Ge, Starkov A, Blass JP, Ratan RR, Beal MF. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta 2010;1802:122-34.
  • Villa RF, Gorini A, Hoyer S. Differentiated effect of ageing on the enzymes of Krebs' cycle, electron transfer complexes and glutamate metabolism of non-synaptic and intra-synaptic mitochondria from cerebral cortex. J Neural Transm 2006;113:1659-70.
  • Ramassamy C. emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. eur J Pharmacol 2006;545:51-64.
  • Freemantle e, Vandal M, Tremblay-Mercier J, Tremblay S, Blachere JC, Begin Me, et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot essent Fatty Acids 2006;75:213-20.
  • Grinberg LT, Thal DR. Vascular pathology in the aged human brain. Acta Neuropathol 2010;119:277-90.
  • Oldendorf WH, Cornford Me, Brown WJ. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1977;1:409-17.
  • Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr 2006;26:1-22.
  • Cunnane SC. Origins and evolution of the Western diet: implications of iodine and seafood intakes for the human brain. Am J Clin Nutr 2005;82:483. author reply 483-4.
  • Goldstein GW. Relation of potassium transport to oxidative metabolism in isolated brain capillaries. J Physiol 1979;286:185-95.
  • Gottstein WJ, eachus AH, Cheney LC. A novel acylation of amino acids with S-carboxymethyl dialkyldithiocarbamates. J Org Chem 1970;35:1693-4.
  • Hasselbalch SG, Knudsen GM, Jakobsen J, Hageman LP, Holm S, Paulson OB. Brain metabolism during short-term starvation in humans. J Cereb Blood Flow Metab 1994;14:125-31.
  • Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 2005;94:1-14.
  • Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 2007;27:1766-91.
  • Cross H, Ferrie C, Lascelles K, Livingston J, Mewasingh L. Old versus newantiepileptic drugs: the SANAD study. Lancet 2007;370:314. author reply 315-6.
  • Wang D, Pascual JM, Yang H, engelstad K, Jhung S, Sun RP, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol 2005;57:111-8.
  • Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, et al. effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004;25:311-4.
  • Bodoky G, Yang ZJ, Meguid MM, Laviano A, Szeverenyi N. effects of fasting, intermittent feeding, or continuous parenteral nutrition on rat liver and brain energy metabolism as assessed by 31P-NMR. Physiol Behav 1995;58:521-7.
  • den Dunnen WF, Brouwer WH, Bijlard e, Kamphuis J, van Linschoten K, eggens-Meijer e, et al. No disease in the brain of a 115-year-old woman. Neurobiol Aging 2008;29:1127-32.
  • Svennerholm L, Bostrom K, Jungbjer B. Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. Acta Neuropathol 1997;94:345-52.
  • de Leon MJ, George Ae, Ferris SH, Christman DR, Fowler JS, Gentes CI, et al. Positron emission tomography and computed tomography assessments of the aging human brain. J Comp Assist Tomog 1984;8:88-94.
  • Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, et al. Brain FDG PeT study of normal aging in Japanese: effect of atrophy correction. eur J Nucl Med Molec Imag 2005;32:794-805.
  • Kochunov P, Ramage Ae, Lancaster JL, Robin DA, Narayana S, Coyle T, et al. Loss of cerebral white matter structural integrity tracks the gray matter metabolic decline in normal aging. NeuroImage 2009;45:17-28.
  • Kety SS. Human cerebral blood flow and oxygen consumption as related to aging. Res Publ Assoc Res Nervous Ment Dis 1956;35:31-45.
  • Dastur DK, Lane MH, Hansen DB, Ketty SS, Butler RN, Perlin S, et al. effects of aging on cerebral circulation and metabolism in man. In: Biren Je, Butler RN, Greenhouse SW, Sokoloff L, Yarrow MR, editors. Human aging: A biological and biochemical study.Washington: US Government Printing Office; 1963. p. 59-78.
  • Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder e, Gur Re. Regional cerebral function determined by FDG-PeT in healthy volunteers: normal patterns and changes with age. J Nucl Med 1995;36:1141-9.
  • Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander Ge, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 1996;16:385-98.
  • Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOe genotype: a prediction study with FDG-PeT. Neurology 2004;63:2332-40.
  • Batovska DI, et al. Antibacterial study of the medium chain fatty acids and their 1-monoglycerides: individual effects and synergistic relationships. Pol J Microbiol 2009;58:43-7.
  • Carpo BG, et al. Novel antibacterial activity of monolaurin compared with conventional antibiotics against organisms from skin infections: an in vitro study. J Drugs Dermatol 6:991-8.
  • eng MG. A new look at coconut oil. 1996. http://www.westonprice.org/knowyourfats/coconut_oil.html
  • eng MG. Coconut: In support of good health in the 21st century. http://www.coconutoil.com/coconut_oil21st_century.htm
  • Freemantle et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot essent Fatty Acids 2006;75:213-220.
  • Freund-Levi Y, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63:1402-8.
  • Gordon S. Coconut oil may help fight childhood pneumonia. http://www.medicinenet.com/script/main/art.asp?articlekey=93828
  • Owen Oe, et al. Rapid intravenous sodium acetoacetate infusion in man. Metabolic and kinetic responses. J Clin Invest 1973;52:2606-16.
  • Pan Y, et al. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutrition 2010;103:1746-54.
  • Petersen RC, et al. Pevalence of mild cognitive impairment is higher in men: The Mayo Clinic Study of Aging. Neurology 2010;75:889-97.
  • Reger MA, et al. effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004;25:311-4.
  • Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev 2009;61:1332-42.
  • Taggart AKP, et al. (D)-ß-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. JBC 2005;280;26649-52.
  • Taha AY, et al. Treating age-related cognitive decline. Neurochem Res 2009;1619-1625).
  • Van Hove, JLK, et al. 2003. D-L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet 2003;36:1433-5. Summary available at http://dx.doi.org/10.1016/S0140-6736(03)13
  • Fukuda N, Yoshitama A, Sugita S, Fujita M, Murukami S. Dietary taurine reduces hepatic secretion of cholesteryl ester and enhances fatty acid oxidation in rats fed a high cholesterol diet. J Nutr Sci Vitaminol (Tokyo). 2011; 57(2): 144-9.
Back to Top
Order Fuel for Thought®

Fuel for Thought® is shipping now. Get some for yourself today!

Buy Now

Our Video

Watch our video to see how the Real Science of Fuel For Thought® supports your cognitive health.

Watch Now

Check Out Our Blog!

Packed with tremendous information surrounding cognitive health, and updated regularly, our blog is a must read!

Visit Our Blog